[L-asparaginase, antithrombin III deficiency and thromboses (author's transl)].
In 2 children treated for acute lymphoblastic leukemia (ALL), sural phlebitis followed treatment with L-asparaginase. The latter was responsible for a decreased synthesis of antithrombin III (AT III) resulting in low plasma activity. Treatment with heparin was not successful and only fresh plasma led to recovery. The activity of AT III, a progressive inhibitor of thrombin and cofactor of heparin, is always below 50% after L-asparaginase. However, since the risk of thrombosis is very low, interruption of treatment and fresh frozen plasma are needed only when additional risk factors are present.
D000293:Adolescent; D020152:Antithrombin III Deficiency; D001215:Asparaginase / Q000009:adverse effects*; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D008297:Male; D010689:Phlebitis / Q000139:chemically induced*; D013927:Thrombosis / Q000517:prevention & control*
D006493:Heparin; D001215:Asparaginase
L-asparaginase, antithrombine III et thromboses.